Art. -Nr.: HY-174803

WMJ-J-09

Kundenbewertung

Based on 1 Customer Validation

WMJ-J-09 is an HDAC inhibitor with IC₅₀ values of 7.5 nM (HDAC1), 21.3 nM (HDAC2), 18.4 nM (HDAC3), 90.9 nM (HDAC8), 3.9 nM (HDAC6) and 8715.7 nM (HDAC4). WMJ-J-09 blocks the cell cycle and induces apoptosis in cancer cells. WMJ-J-09 induces cancer cell death through the LKB1-AMPK-p38MAPK-p63-survivin signaling cascade.WMJ-J-09 inhibits HDAC enzyme activity, leading to acetylation of key proteins and thereby regulating cancer cell death. WMJ-J-09 can be used in HCT116 cells and FaDu cells research^[1][2].

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.44%
CAS. Nr.: 2416914-29-7
Formel: C₂₂H₂₇N₃O₅S
Molecular Weight:445.53

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

WMJ-J-09 Chemical Structure

CAS. Nr.: 2416914-29-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle HDAC Isoform-spezifische Produkte anzeigen :

Alle AMPK Isoform-spezifische Produkte anzeigen :

Alle Pim Isoform-spezifische Produkte anzeigen :

In Vitro

WMJ-J-09 (compound WMJ-J-09) (0-10 μM, 48 h, CRC cells) (0-20 μM, 72 h, HNSCC cells) selectively kills cancer cells in a concentration- and time-dependent manner, and exerts no significant toxicity on non-tumor FHC cells^[1][2].

WMJ-J-09 (5 μM, 24 h, HCT116 cells) (10 μM, 48 h, FaDu cells) arrests the cell cycle of cancer cells at the G2/M phase and induces apoptosis^[1][2].

WMJ-J-09 (5 μM, 24 h, HCT116 cells) (10 μM, 24 h, FaDu cells) disrupts microtubule assembly^[1][2].

WMJ-J-09 (5 μM, 6-24 h, HCT116 cells) (10 μM, 24 h, FaDu cells) inhibits survivin at the transcriptional level^[1][2].

WMJ-J-09 (0-10 μM, 24 h, HCT116 cells) (0-20 μM, 48 h, FaDu cells) regulates signaling pathways in cancer cells, inhibits HDACs to modulate key proteins, and promotes cancer cell apoptosis^[1][2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]^[2]

Cell Line:

HCT116 cells, FHC cells; FaDu cells, SCC9 cells, SCC25 cells
Concentration:

0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM (HCT116 cells, FHC cells); 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells, SCC9 cells, SCC25 cells)
Incubation Time:

48 h (HCT116 cells, FHC cells); 72 h (FaDu cells, SCC9 cells, SCC25 cells)
Result:

Reduced the viability of CRC cells (with significant inhibition at 10 μM and an IC₅₀ of approximately 5 μM).
Had the strongest inhibitory effect on cell viability at 10 μM, and the survival rate of FaDu cells dropped to about 30 % after treatment with 20 μM for 72 h.

Apoptosis Analysis^[1]^[2]

Cell Line:

HCT116 cells; FaDu cells
Concentration:

5 μM (HCT116 cells); 10 μM (FaDu cells)
Incubation Time:

24 h (HCT116 cells); 48 h (FaDu cells)
Result:

Increased the proportion of early apoptotic (LR quadrant) and late apoptotic (UR quadrant) cells.
Increased cleaved caspase-3 and PARP cleavage fragments.
Significantly increased the proportion of sub-G1 phase (apoptotic cells), with approximately 40 % at 20 μM.

Cell Cycle Analysis^[1]^[2]

Cell Line:

HCT116 cells; FaDu cells
Concentration:

5 μM (HCT116 cells); 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells)
Incubation Time:

24 h
Result:

Reduced the proportion of cells in the S phase and increased the proportion of cells in the G2/M phase and sub-G1 phase (apoptosis peak).
Increased the proportion of cells in the G2/M phase (from 12 % to 28 % at 10 μM) and decreased the number of cells in the S phase.

Immunofluorescence^[1]^[2]

Cell Line:

HCT116 cells; FaDu cells
Concentration:

5 μM (HCT116 cells); 10 μM (FaDu cells)
Incubation Time:

24 h
Result:

Disrupted the cytoskeleton through α-tubulin acetylation.

RT-PCR^[1]^[2]

Cell Line:

HCT116 cells; FaDu cells
Concentration:

5 μM (HCT116 cells); 10 μM (FaDu cells)
Incubation Time:

6-24 h (HCT116 cells); 6 h (FaDu cells)
Result:

Inhibited survivin expression at the transcriptional level.

Western Blot Analysis^[1]^[2]

Cell Line:

HCT116 cells, HCT116 p53-/- cells, HCT116-p53 wildtype cells; FaDu cells
Concentration:

0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM (HCT116 cells, HCT116 p53-/- cells, HCT116-p53 wildtype cells); 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells)
Incubation Time:

24 h (HCT116 cells, HCT116 p53-/- cells, HCT116-p53 wildtype cells); 48 h (FaDu cells)
Result:

Increased p21 protein, acetylated and phosphorylated p53, decreased survivin protein, and increased α-tubulin acetylation.
Activated phosphorylation of the LKB1/p38MAPK pathway.
Acetylated survivin and degraded it in the proteasome.
Increased p21 protein significantly, while cyclin D1 and survivin proteins decreased.
Increased the phosphorylation levels of LKB1 (Ser 428), AMPK (Thr 172), p38MAPK (Thr 180/Tyr 182), and p63 (Ser 160/162) over time, and increased cleaved caspase-3 and PARP (apoptosis markers).

In Vivo

WMJ-J-09 (compound WMJ-J-09) (20 mg/kg, i.p, daily for 19 days) inhibits CRC tumor growth by inhibiting cancer cell proliferation and is well tolerated in the HCT116 xenograft mice model^[1].

WMJ-J-09 (20 mg/kg, i.p, daily for 23 days) inhibits the growth of HNSCC transplanted tumors and has good safety^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

HCT116 xenograft model established in nude male mice(4 weeks)^[1]
Dosage:

20 mg/kg
Administration:

Daily intraperitoneal injection (i.p.), at the corresponding doses for 19 days
Result:

Inhibited tumor growth, with tumor volume and weight significantly lower than those in the control group.
Inhibited tumor proliferation, as indicated by reduced Ki67 immunohistochemical staining within the tumor.
Exhibited low toxicity, with no significant change in mouse body weight.

Animal Model:

DaFu xenograft model established in nude male mice(4 weeks, 25g)^[2]
Dosage:

20 mg/kg
Administration:

Daily intraperitoneal injection (i.p.), at the corresponding doses for 23 days.
Result:

Significantly inhibited tumor growth, with the average tumor weight in the treatment group lower than that in the control group.
Exhibited low toxicity, with no significant change in mouse body weight.

Chemical Information

CAS. Nr. 2416914-29-7
Appearance Solid
Molecular Weight 445.53
Formel C₂₂H₂₇N₃O₅S
Color White to off-white
SMILES

O=C(NO)CCCCCCC(NC1=CC(N(S(C2=CC=CC=C2)(=O)=O)CC3)=C3C=C1)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (561.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2445 mL

11.2226 mL

22.4452 mL

5 mM

0.4489 mL

2.2445 mL

4.4890 mL

10 mM

0.2245 mL

1.1223 mL

2.2445 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hanhuang Yu, et al. The hydroxamate based HDAC inhibitor WMJ-J-09 induces [Content Brief]

[2]. Chia-Sheng Yen, et al. A Novel Hydroxamate-Based Compound WMJ-J-09 Causes Head and Neck Squamous Cell Carcinoma Cell Death via LKB1-AMPK-p38MAPK-p63-Survivin Cascade. Front Pharmacol. 2018 Mar 1. 9:167. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2445 mL	11.2226 mL	22.4452 mL	56.1129 mL
	5 mM	0.4489 mL	2.2445 mL	4.4890 mL	11.2226 mL
	10 mM	0.2245 mL	1.1223 mL	2.2445 mL	5.6113 mL
	15 mM	0.1496 mL	0.7482 mL	1.4963 mL	3.7409 mL
	20 mM	0.1122 mL	0.5611 mL	1.1223 mL	2.8056 mL
	25 mM	0.0898 mL	0.4489 mL	0.8978 mL	2.2445 mL
	30 mM	0.0748 mL	0.3741 mL	0.7482 mL	1.8704 mL
	40 mM	0.0561 mL	0.2806 mL	0.5611 mL	1.4028 mL
	50 mM	0.0449 mL	0.2245 mL	0.4489 mL	1.1223 mL
	60 mM	0.0374 mL	0.1870 mL	0.3741 mL	0.9352 mL
	80 mM	0.0281 mL	0.1403 mL	0.2806 mL	0.7014 mL
	100 mM	0.0224 mL	0.1122 mL	0.2245 mL	0.5611 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

WMJ-J-09

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

MAPK Compound Library

PI3K/Akt/mTOR Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Osteogenesis Compound Library

Pain-Related Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Alle HDAC Isoform-spezifische Produkte anzeigen

Alle AMPK Isoform-spezifische Produkte anzeigen

Alle Pim Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

WMJ-J-09 Related Classifications

HY-174803 Related Classifications